Nine patients with advanced Hodgkin's lymphoma (HL) who had undergone allogeneic stem cell transplantation (allo-SCT) received donor leukocyte infusions (DLIs) for treatment of persistent or progressive disease (PD). A total of 15 DLIs were performed, with four patients receiving more than one DLI. In four patients, prior salvage chemotherapy was administered. The median CD3 þ cell dose administered was 77.5 Â 10 6 /kg (range 5-285). GVHD developed in all but one patient. The response rate was 4/9 (44%). Three of these four responders developed GVHD and 3/4 had received chemotherapy. No correlation was observed between CD3 þ cell dose infused and disease response. At the latest follow-up, three patients are alive and six have expired (PD n ¼ 3, nonrelapse mortality n ¼ 3). The median response duration was 7 months (range 4-9), with one response currently ongoing. These data suggest that DLIs for immunotherapy of recurrent HL have significant activity, although they frequently leads to GVHD. The small sample size does not allow any conclusion as to whether chemotherapy administration increases the chance of response. The CD3 cell dose infused does not seem to correlate with disease response.
/kg (range . GVHD developed in all but one patient. The response rate was 4/9 (44%). Three of these four responders developed GVHD and 3/4 had received chemotherapy. No correlation was observed between CD3 þ cell dose infused and disease response. At the latest follow-up, three patients are alive and six have expired (PD n ¼ 3, nonrelapse mortality n ¼ 3). The median response duration was 7 months (range 4-9), with one response currently ongoing. These data suggest that DLIs for immunotherapy of recurrent HL have significant activity, although they frequently leads to GVHD. The small sample size does not allow any conclusion as to whether chemotherapy administration increases the chance of response. The CD3 cell dose infused does not seem to correlate with disease response. allogeneic bone marrow transplantation; donor leukocyte infusions; donor lymphocyte infusions Donor leukocyte infusions (DLIs) have gained a prominent role in the management of patients who relapse following allogeneic stem cell transplantation (allo-SCT) from both matched related and unrelated donors. [1] [2] [3] Their efficacy has provided powerful evidence supporting the existence of a graft-versus-malignancy effect. Most of the patients reported in the literature had either chronic myeloid leukemia (CML) or acute leukemia , both myeloid or lymphoid. [2] [3] The efficacy of post-allo-SCT DLIs seems most apparent in CML patients, where the impact of the T-cell dose on outcome (ie development of GVHD and response) has been demonstrated. [4] [5] Experience with DLIs in Hodgkin's lymphoma (HL) remains scarce, [6] [7] [8] and the very existence of a graft-versusHodgkin's effect remains controversial. Because of the paucity of data, the impact (if any) of the T-cell dose on clinical outcome has been uncertain. In this study, we review our experience with DLIs as adoptive immunotherapy in HL patients in the treatment of post-allo-SCT relapse.
Patients and methods
Over a 5-year period (January 1999-January 2004), 51 patients underwent allografts from a matched related or unrelated donor for refractory or relapsed HL at our center. In all, 25 of them (49%) had persistent or progressive disease (PD) after allo-SCT. All patients in this group who received one or more DLI (with or without preceding salvage chemotherapy) for the management of PD following allo-SCT are included in this study. The treatment plan for the patients was approved by our institution's Institutional Review Board (IRB), and all patients provided written informed consent.
The conditioning regimen for these patients included in all but one case fludarabine with melphalan or cyclophosphamide. One patient received busulfan-based conditioning. Three patients received antithymocyte globulin as part of their preparative regimen. There was no manipulation of the stem cell product infused. GVHD prophylaxis consisted of tacrolimus and methotrexate. Chimerism was determined beginning on day 30 post transplant on bone marrow and/or peripheral blood samples by restriction fragment length polymorphism (RFLP) and, more recently, with PCR-based microsatellite polymorphism analysis using established criteria.
When PD was confirmed, patients had their immunosuppression (tacrolimus, corticosteroids) tapered if still being administered. Patients were included regardless of the nature of the cell product infused (filgrastim-mobilized peripheral blood progenitor cells vs unmobilized donor leukocytes). PD patients received DLIs (as opposed to salvage chemotherapy and/or radiation therapy only) at the discretion of the attending physician. In patients receiving more than one DLI, a consistent CD3 þ dose-escalation scheme was not followed. Salvage chemotherapy was also administered prior to the DLI at the discretion of the attending physician.
Response criteria employed were similar to the ones described previously. 9 CRU was defined as the presence of stable minimal residual physical or radiographic abnormality of unknown significance for a minimum of 4 weeks, not believed to represent residual or active malignancy. Positron emission tomography (PET) or gallium scan should be negative if performed. CRUs are reclassified as complete responses after 12 months of follow-up.
The primary end point was the relationship between T-cell dose (CD3 þ ) infused and either the development of GHVD or disease response. However, the evaluation of these associations was limited in view of the small sample size and the small number of observed outcomes of interest. The distribution of cell dose according to response was compared using the Mann-Whitney rank-sum test. The association with GVHD could not be evaluated statistically because all except one patient developed GVHD. Descriptive data are presented in Table 1 .
Results
Nine patients with relapsed or refractory HL following allo-SCT (36% of the total) were treated with DLIs (Table 1) . Their median age was 30 years (range 18-42), and seven (78%) had failed a prior autologous SCT. The median number of prior chemotherapy regimens was four (range 3-8) and seven had received prior radiation therapy. Seven had a matched sibling donor and two a matched unrelated donor. A total of 15 DLIs were performed (ie four patients received more than one DLI), and in four patients prior salvage chemotherapy was administered. The median time from allo-SCT to DLI was 7 months (range 4-29). The pre-DLI chimerism status was 2/9 mixed and 7/9 full donor. The median CD3 þ cell dose administered was 77.5 Â 10 6 /kg (range 5-285). GVHD developed following the DLI in all but one patient. After the DLI, the two patients exhibiting mixed chimerism achieved complete or near-complete donor chimerism.
The response rate (complete plus partial response) was 4/9 (44%). All of the responses qualified as CRUs. Three of these four responders developed GVHD and three of them had received chemotherapy. As shown in Table 1 , the median duration of response after DLI was 7 months (range 4-9). In two cases (UPN 990031 and UPN 030009) , the DLI response duration outlasted the one obtained with the allo-SCT preparative regimen. No correlation was observed between CD3 þ cell dose infused and response. The distribution of CD3 þ cell dose infused was not significantly different (P ¼ 0.5) among patients who responded (median 91.24 Â 10 6 /kg, range 56-108) and those who did not (median 63 Â 10 6 /kg, range 5-285). Of the four patients who had received chemotherapy, three (75%) responded, while only one of the five patients who did not had a response (20%; P ¼ 0.2 Fisher's exact test). At the latest follow-up, three patients are alive (one in CRU) and six have expired (PD n ¼ 3, nonrelapse mortality n ¼ 3).
Discussion
Published data on DLIs in HL are limited to a few published studies, and the very existence of a graft-versus-HL effect following allo-SCT remains a matter of controversy. [10] [11] [12] [13] The latter has been postulated by several investigators.
6,11,14 Milpied et al 11 showed a lower relapse rate in allografted HL patients with grade 2-4 acute GVHD when compared to HL patients who had received an autograft. Similarly, Akpek et al 14 reported a clear trend toward a lower relapse rate in HL patients allografted in chemosensitive relapse and in patients who developed GVHD. It is conceivable that the high cumulative transplant-related mortality in allo-SCT for HL found in registry studies (50-60%) may have obscured the presence of such an effect. 10, 11 The most convincing proof of principle for a graftversus-HL effect is likely to come from the experience with DLIs. Porter et al 8 reported four cases of DLIs post-auto-SCT preceded by interferon treatment in three of them, with one complete and one minor response. After the initial publication from Branson et al, 7 in a recent update, the same group reported 19 HL patients (three with preceding salvage chemotherapy) out of a cohort of 41 originally transplanted who received DLIs for residual disease or disease progression (n ¼ 16) or mixed chimerism (n ¼ 3) following allo-SCT. About a third of the patients developed GVHD, and DLI-related mortality was 11%. 6 The response rate was 9/16 (56%) of the evaluable patients. Two of these responders had received prior chemotherapy, although none of the five maintained responses was in chemotherapy-treated patients. A comparison between this response rate and the one we experienced is made difficult by the fact that salvage chemotherapy was administered in 3/19 (16%) of these patients, vs 4/9 (44%) of our patients. In addition, the authors employed alemtuzumab-based conditioning in all patients, which may have increased the chance of response to the DLI. Indeed, the high early progression rate seemingly observed in this setting (characterized by a profound B-and T-cell depletion in the infused graft) could be interpreted as indirect evidence supporting a graft-versus-HL effect. The issue of a possible correlation between T-cell dose infused and clinical outcome (GVHD, response) was not explored by the latter two studies. A similar correlation has been shown to be present in diseases like CML. 4, 5 In summary, despite the obvious study limitations related to the small sample size, patient heterogeneity and concomitant chemotherapy administration, these data suggest that DLIs for immunotherapy of recurrent HL following allo-SCT have significant activity. The small sample size does not allow any meaningful conclusion on whether chemotherapy administration will increase the chance of response. These data also suggest that DLIs lead to complete or near-complete donor chimerism (if not already present) as well as, in the majority of cases, GVHD. The T-cell (ie CD3 þ ) cell dose infused does not seem to correlate with clinical outcome parameters such as disease response.
